

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Binie V. Lipps
Frederick W. Lipps

Serial No.: 10/047,945

Filed: January 14, 2002

For: DIAGNOSIS AND TREATMENT
FOR IMMUNOGLOBULIN E (IgE)
IMPLICATED DISORDERS

SATTY DCKT NO: FWLPAT015US

ATTY DCKT NO: FWLPAT015US

Examiner:

S

Examiner:

S

Examiner:

S

Examiner:

S

Examiner:

S

FOR IMMUNOGLOBULIN E (IgE)
S

IMPLICATED DISORDERS

Commissioner of Patent and Trademarks Washington, DC 20231

RESPONSE

Honorable Commissioner:

In response to a requirement mailed March 15, 2002 to comply with requirements for patent applications containing amino acid sequence disclosures, (copy attached) please consider the following:

The sequence listing information recorded in computer readable form and submitted with the application is identical to the written sequence listing submitted with the application. No new matter is presented.

Reconsideration and withdrawal of the requirement is requested.

Please mail correspondence to:

John R. Casperson PO Box 2174 Friendswood, Texas 77549


Tel. No. 281-482-2961

Respectfull submitted:

3-26-02

John R. Casperson

Reg. No. 28,198



UNITED STATES PA

Unixed States Patent and Trademark Office

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
WWW.uspto.gov

APPLICATION NUMBER FILING/RECEIPT DATE FIRST NAMED APPLICANT ATTORNEY DOCKET NUMBER

10/047,945

01/14/2002

Binie V. Lipps

FWLPAT015US

CONFIRMATION NO. 5192
FORMALITIES LETTER
OC000000007645467

John R. Casperson PO Box 2174 Friendswood, TX 77549

Date Mailed: 03/15/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



COPY OF PAPERS ORIGINALLY FILED

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

§

§

99999

In re application of: Binie V. Lipps

Frederick W. Lipps

Serial No.: 10/047,945

Filed: January 14, 2002

For: DIAGNOSIS AND TREATMENT FOR IMMUNOGLOBULIN E (IgE) IMPLICATED DISORDERS

ATTY DCKT NO: FWLPAT015US

4

Art Unit: 1645

Examiner:

Commissioner of Patent and Trademarks Washington, DC 20231

Sir:

Transmitted herewith for filing in the captioned application is:

- (a) A Response to a Requirement dated March 15, 2002 to submit a statement that the CRF copy and the paper copy of the sequence listing are identical; and
- (b) A copy of the Notice

Please mail correspondence to:

John R. Casperson PO Box 2174 Friendswood, Texas 77549

Tel. No. 281-482-2961

Respectfully submitted

John R. Casperson

Reg. No. 28,198

I hereby certify that this correspondence and all documents referred to herein is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231 on

2002

by John R. Casperson, Reg. No. 28,198 (date)